HAYA Therapeutics
Marco Mina is an experienced professional in computational biology, currently serving as Director of Computational Biology at HAYA Therapeutics SA since October 2021. Prior to this role, Marco held the position of Manager of Data Science and Bioinformatics at SOPHiA GENETICS from March 2020 to September 2021 and completed a postdoctoral fellowship at UNIL - Université de Lausanne focusing on cancer research and cancer omics from September 2015 to March 2020. Marco's earlier experience includes working as a Research and Development Scientist at MPBA, Fondazione Bruno Kessler, and as a PhD Student in Bioinformatics at the University of Padova, where research centered on network alignment algorithms. Educational achievements include a Master's and Bachelor’s degree in Computer Science and Computer Engineering from the University of Padova, along with a high school diploma from Liceo Scientifico, Brandolini-Rota in Italy.
This person is not in any offices
HAYA Therapeutics
1 followers
HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.
Industries
Employees
11-50